• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿莫达非尼治疗双相情感障碍的药代动力学评价。

Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression.

机构信息

Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Antwerp, Belgium.

出版信息

Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1189-97. doi: 10.1517/17425255.2012.708338. Epub 2012 Jul 18.

DOI:10.1517/17425255.2012.708338
PMID:22803602
Abstract

INTRODUCTION

Bipolar disorder is a psychiatric illness with recurring episodes of mania and depression. Armodafinil , the R-enantiomer of modafinil, approved for treating excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder, is possibly effective as an adjunctive treatment for bipolar depression.

AREAS COVERED

This review covers the pharmacokinetics of armodafinil, with an emphasis on its use in bipolar depression. Its clinical efficacy in the treatment of bipolar depression is evaluated, along with current data regarding its safety and tolerability.

EXPERT OPINION

One placebo-controlled trial is available, in which armodafinil was efficacious as an adjunctive treatment in bipolar depression. Armodafinil shows a linear pharmacokinetic profile over a broad dose range of 50 - 400 mg (maximal plasma concentration and area under concentration-time curve). Compared with modafinil, an equivalent dose of armodafinil attains higher blood concentrations 4 - 6 h post-dose. The possibility of drug interactions is generally low, although interactions have been shown with some drugs used in bipolar disorder, through mild CYP3A4-induction and CYP2C19-inhibition. Armodafinil is well tolerated and presents a possible new treatment option for bipolar depression. However, further investigation is still needed in order to confirm its efficacy and to clarify its role in the treatment of bipolar depression.

摘要

简介

双相情感障碍是一种反复发作的躁狂和抑郁的精神疾病。阿莫达非尼,莫达非尼的 R-对映体,被批准用于治疗与嗜睡症、阻塞性睡眠呼吸暂停和轮班工作障碍相关的过度嗜睡,可能对双相抑郁的辅助治疗有效。

涵盖领域

本综述涵盖了阿莫达非尼的药代动力学,重点介绍了其在双相抑郁中的应用。评估了其在治疗双相抑郁中的临床疗效,以及关于其安全性和耐受性的最新数据。

专家意见

目前只有一项安慰剂对照试验可用,其中阿莫达非尼作为双相抑郁的辅助治疗有效。阿莫达非尼在 50-400mg 宽剂量范围内呈现线性药代动力学特征(最大血浆浓度和浓度-时间曲线下面积)。与莫达非尼相比,等剂量的阿莫达非尼在给药后 4-6 小时达到更高的血药浓度。药物相互作用的可能性通常较低,尽管已显示与一些用于治疗双相情感障碍的药物存在相互作用,通过轻度 CYP3A4 诱导和 CYP2C19 抑制。阿莫达非尼耐受性良好,为双相抑郁提供了一种新的可能治疗选择。然而,仍需要进一步研究以确认其疗效,并阐明其在治疗双相抑郁中的作用。

相似文献

1
Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression.阿莫达非尼治疗双相情感障碍的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1189-97. doi: 10.1517/17425255.2012.708338. Epub 2012 Jul 18.
2
Armodafinil in the treatment of excessive sleepiness.阿莫达非尼治疗过度嗜睡。
Expert Opin Pharmacother. 2010 Apr;11(6):993-1002. doi: 10.1517/14656561003705738.
3
Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.健康受试者中阿得拉非尼的药代动力学特征:三项随机研究数据的汇总分析
Clin Drug Investig. 2009;29(2):87-100. doi: 10.2165/0044011-200929020-00003.
4
Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat.阿莫达非尼,莫达非尼的R-对映体:在大鼠中的促觉醒作用及药代动力学特征
Pharmacol Biochem Behav. 2006 Nov;85(3):492-9. doi: 10.1016/j.pbb.2006.09.018. Epub 2006 Nov 28.
5
A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.一项关于阿莫达非尼治疗治疗性阻塞性睡眠呼吸暂停伴发抑郁患者过度嗜睡的双盲、安慰剂对照研究。
J Clin Psychiatry. 2010 Jan;71(1):32-40. doi: 10.4088/JCP.09m05536gry. Epub 2009 Dec 29.
6
Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss.急性睡眠剥夺夜间时段单剂量阿戈美拉汀对健康受试者警觉性的药效学影响。 (注:原文中药物名称有误,正确的应该是armodafinil,翻译为阿戈美拉汀) 经修正后正确译文:急性睡眠剥夺夜间时段单剂量阿莫达非尼对健康受试者警觉性的药效学影响。
Curr Med Res Opin. 2006 Jan;22(1):159-67. doi: 10.1185/030079906X80378.
7
Armodafinil for excessive daytime sleepiness.阿莫达非尼治疗日间过度嗜睡。
Drugs Today (Barc). 2008 Jun;44(6):395-414. doi: 10.1358/dot.2008.44.6.1195861.
8
Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.阿莫达非尼在健康老年男性与年轻男性中的全身暴露情况及其耐受性:一项开放标签、多剂量、平行组研究。
Drugs Aging. 2011 Feb 1;28(2):139-50. doi: 10.2165/11586370-000000000-00000.
9
Stimulants for treating bipolar disorder: pro and con.治疗双相情感障碍的兴奋剂:利弊
Harv Rev Psychiatry. 2014 Nov-Dec;22(6):358-62. doi: 10.1097/HRP.0000000000000003.
10
Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: a randomized, open-label, crossover study.在治疗性阻塞性睡眠呼吸暂停相关过度嗜睡患者中,单次和多次给药后阿莫达非尼和莫达非尼的药代动力学:一项随机、开放标签、交叉研究。
Clin Ther. 2010 Nov;32(12):2074-87. doi: 10.1016/j.clinthera.2010.11.009.

引用本文的文献

1
Evaluation of the potential for a pharmacokinetic drug-drug interaction between armodafinil and ziprasidone in healthy adults.健康成年人中阿莫达非尼与齐拉西酮之间药代动力学药物相互作用可能性的评估。
Clin Drug Investig. 2014 Oct;34(10):691-9. doi: 10.1007/s40261-014-0220-3.
2
Assessing the roles of stimulants/stimulant-like drugs and dopamine-agonists in the treatment of bipolar depression.评估兴奋剂/类兴奋剂药物和多巴胺激动剂在双相情感障碍治疗中的作用。
Curr Psychiatry Rep. 2013 Aug;15(8):378. doi: 10.1007/s11920-013-0378-z.